PVR and neoplasm: Second, this study did not compare the associations between TLSs and tumor mutational burden (TMB), and immune checkpoint receptors and ligands (such as programmed cell death 1 receptor (PD‐1) and its ligand (PD‐L1/PD‐L2), T cell immunoreceptor with Ig and ITIM domains (TIGIT), CD155, etc.), which will be explored in our future studies.